Absent or decreased expression of Smad4 has been demonstrated in various cancers, including pancreatic, colorectal, head and neck (16,17), and, more recently, in papillary thyroid carcinomas (PTCs) (18), suggesting that the TGF-β signaling functions as a tumor suppressor. Here, SMAD4 is linked to differentiated thyroid carcinoma.